800 related articles for article (PubMed ID: 34364110)
21. Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19.
Melton JD; Wilson K; Blind F; Barbera A; Bhisitkul D; Hasara S; Homa K; Karp J; Escowitz H; Haber T; DeGroot D; Anderson J; DeLeon J; Santos JL; Faviere D; Fuell J; Gillespie R; Glueck J; Reeber C; Rhodes DJ; Rodriguez V
Am J Emerg Med; 2021 Dec; 50():437-441. PubMed ID: 34487951
[TBL] [Abstract][Full Text] [Related]
22. Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.
Haskologlu IC; Erdag E; Sayiner S; Abacioglu N; Sehirli AO
Mol Biol Rep; 2022 May; 49(5):4061-4068. PubMed ID: 35389130
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
[No Abstract] [Full Text] [Related]
24. Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.
Phan AT; Gukasyan J; Arabian S; Wang S; Neeki MM
Cureus; 2021 May; 13(5):e15280. PubMed ID: 34194882
[TBL] [Abstract][Full Text] [Related]
25. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities.
Tulledge-Scheitel S; Bell SJ; Larsen JJ; Bierle DM; Takahashi P; Moehnke DE; Destro Borgen MJ; Springer DJ; Reinschmidt KJ; Baumbach LJ; Matoush JA; Heyliger A; Hanson SN; Razonable RR; Ganesh R
J Am Geriatr Soc; 2021 Apr; 69(4):868-873. PubMed ID: 33619724
[TBL] [Abstract][Full Text] [Related]
26. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
Destache CJ; Aurit SJ; Schmidt D; Peet Erkes L; Tierney M; Vivekanandan R
Pharmacotherapy; 2021 Sep; 41(9):743-747. PubMed ID: 34328670
[TBL] [Abstract][Full Text] [Related]
27. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
Buonomo AR; Filippo ID; Esposito N; Saccone G; Nobile M; Viceconte G; Villari R; Carlo CD; Bifulco G; Gentile I
Am J Perinatol; 2024 Feb; 41(3):365-367. PubMed ID: 37072016
[TBL] [Abstract][Full Text] [Related]
28. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
[TBL] [Abstract][Full Text] [Related]
29. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
30. Casirivimab and Imdevimab for Pregnant Women Hospitalized for Severe Coronavirus Disease 2019.
Riccardo BA; Gabriele S; Nunzia E; Isabella DF; Biagio P; Maria F; Emanuela Z; Agnese G; Nicola SM; Giulio V; Riccardo S; Giuseppe B; Ivan G
Am J Perinatol; 2024 May; 41(S 01):e612-e616. PubMed ID: 35973799
[TBL] [Abstract][Full Text] [Related]
31. Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals.
Quenzer FC; Lafree AT; Grey L; Singh S; Smyers C; Balog B; Guedez HM; McIntyre K; Wulfovich S; Ramirez J; Saikhon T; Tomaszewski C
West J Emerg Med; 2022 Mar; 23(3):302-311. PubMed ID: 35679495
[TBL] [Abstract][Full Text] [Related]
32. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
Trials; 2021 May; 22(1):363. PubMed ID: 34034784
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
[No Abstract] [Full Text] [Related]
34. Casirivimab/Imdevimab: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(17):2047-2055. PubMed ID: 34716907
[TBL] [Abstract][Full Text] [Related]
35. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
Takemoto K
Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
[TBL] [Abstract][Full Text] [Related]
36. Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders.
Stein D; Oviedo-Orta E; Kampman WA; McGinniss J; Betts G; McDermott M; Holly B; Lancaster JM; Braunstein N; Yancopoulos GD; Weinreich DM
Clin Infect Dis; 2022 Aug; 75(1):e509-e515. PubMed ID: 34971385
[TBL] [Abstract][Full Text] [Related]
37. Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
Sobolewski KA; Smoke SM; Brophy A; Vassallo AV; Chen B; Hilden P; Patterson R; Pittiglio M; Raja K; Handler E; Freer C
J Med Virol; 2022 Jun; 94(6):2493-2499. PubMed ID: 35199356
[TBL] [Abstract][Full Text] [Related]
38. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
Baum A; Ajithdoss D; Copin R; Zhou A; Lanza K; Negron N; Ni M; Wei Y; Mohammadi K; Musser B; Atwal GS; Oyejide A; Goez-Gazi Y; Dutton J; Clemmons E; Staples HM; Bartley C; Klaffke B; Alfson K; Gazi M; Gonzalez O; Dick E; Carrion R; Pessaint L; Porto M; Cook A; Brown R; Ali V; Greenhouse J; Taylor T; Andersen H; Lewis MG; Stahl N; Murphy AJ; Yancopoulos GD; Kyratsous CA
Science; 2020 Nov; 370(6520):1110-1115. PubMed ID: 33037066
[TBL] [Abstract][Full Text] [Related]
39. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
40. Bamlanivimab Use in a Military Treatment Facility.
Karr E; Chung T; Burtson K; Markert R; Kelly D
Mil Med; 2022 Oct; 187(11-12):e1261-e1264. PubMed ID: 33993281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
